# MUBD-DecoyMaker2.0

Introduction
-----------------------------------

MUBD-DecoyMaker2.0, an updated version of MUBD-DECOYMAKER, is a Python GUI application to generate maximal unbiased benchmarking sets data sets for virtual drug screening. It can be run on Windows-based machine and has no dependency. 

Availability & Implementation
-----------------------------------

* Due to the large size, the Python GUI application has been uploaded to the cloud drives and is accessible from there：
  https://www.dropbox.com/s/dfa35t2jb0fnarx/MUBD-DecoyMaker2.0.exe?dl=0     (Outside China) or
  https://pan.baidu.com/s/110FJY6YHxcaUmI7fSyUSkw  (China)


Documentation
-----------------------------------

* The manual for the Python GUI application and the files for the case study are available at this website, i.e. 'manual.for.MUBD-Decoymaker2.0.pdf' and 'Case-ACM4-Agonists.zip'.


Installation
-----------------------------------

* We recommend the users to run the Python GUI application on Windows-based machines, as all the dependencies have been included. Please note we used the machine with Intel Core(TM) i7-7700 CPU@3.60GHz and RAM of 16 GB for testing the tool. The computation time for the test case of ACM Agonists was 1882 seconds. 
 


References
-----------------------------------
Computational tool, Methodology and Datasets:
1. Xia, J., Li, S., Ding, Y., Wu, S. and Wang, X.S., MUBD‐DecoyMaker 2.0: A Python GUI Application to Generate Maximal Unbiased Benchmarking Data Sets for Virtual Drug Screening. Mol. Inf.,2020, 39, 1900151. 
https://doi.org/10.1002/minf.201900151 (Tool)
2. Xia, J.; Jin, H.; Liu, Z.; Zhang, L.; Wang, X.S., An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to GPCRs. J. Chem. Inf. Model., 2014, 54 (5): 1433-1450. 
https://pubs.acs.org/doi/10.1021/ci500062f  (Algorithm and MUBD-GPCRs/ULS/UDS)
3. Xia, J.; Tilahun, E.L.; Kebede, E.H.; Reid, T.E.; Zhang, L.;Wang, X.S.,Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. J. Chem. Inf. Model., 2015, 55 (2): 374-388. 
https://pubs.acs.org/doi/10.1021/ci5005515  (MUBD-HDACs)
4. Xia, J.; Reid, T.E.; Wu, S.; Zhang, L.; Wang, X.S., Maximal Unbiased Benchmarking Data Sets for Human Chemokine Receptors and Comparative Analysis. J. Chem. Inf. Model., 2018, 58 (5): 1104-1120. 
https://pubs.acs.org/doi/10.1021/acs.jcim.8b00004 (MUBD-hCRs)

Selected Applications of MUBD:
 Zheng, L.; Bao, Y.; Sun, L.; Yu, C.; Sun, Y.; Song, Z.; Wang, G.; Huang, Y.; Li, Y., An Improved Protocol for the Virtual Screening Discovery of Novel Histone Deacetylase Inhibitors. Chem. Pharm. Bull. 2019, 67 (10), 1076-1081. https://doi.org/10.1248/cpb.c19-00321
Kong, Y.; Bender, A.; Yan, A., Identification of Novel Aurora Kinase a (Aurka) Inhibitors Via Hierarchical Ligand-Based Virtual Screening. J. Chem. Inf. Model., 2018, 58, 36-47.  https://doi.org/10.1021/acs.jcim.7b00300
Zhou, H.; Cao, H.; Skolnick, J., FINDSITEcomb2.0: A New Approach for Virtual Ligand Screening of Proteins and Virtual Target Screening of Biomolecules. J. Chem. Inf. Model. 2018, 58 (11), 2343-2354. https://doi.org/10.1021/acs.jcim.8b00309
Dou, X.; Jiang, L.; Wang, Y.; Jin, H.; Liu, Z.; Zhang, L., Discovery of New Gsk-3beta Inhibitors through Structure-Based Virtual Screening. Bioorg. Med. Chem. Lett., 2018, 28, 160-166. https://doi.org/10.1016/j.bmcl.2017.11.036
Huang, Yx., Zhao, J., Song, Qh. et al. Virtual screening and experimental validation of novel histone deacetylase inhibitors. BMC Pharmacol Toxicol 17, 32 (2016). https://doi.org/10.1186/s40360-016-0075-8
Pei, F., Jin, H., Zhou, X., Xia, J., Sun, L., Liu, Z. and Zhang, L. (2015), Enrichment Assessment of Multiple Virtual Screening Strategies for Toll-Like Receptor 8 Agonists Based on a Maximal Unbiased Benchmarking Data Set. Chem Biol Drug Des, 86: 1226-1241.  https://doi.org/10.1111/cbdd.12590


